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Public perception of the safety and efﬁcacy of
childhood vaccines has a direct impact on
immunization rates (Biroscak et al. 2003;
Thomas et al. 2004). The current debate link-
ing the use of thimerosal in vaccines to autism
and other developmental disorders [Institute
of Medicine (IOM) 2001, 2004] has led many
families to question whether the potential risks
associated with early childhood immuniza-
tions may outweigh the beneﬁts (Blaxill et al.
2004; SafeMinds 2005). Thimerosal is an
effective preservative that has been used in the
manufacturing of vaccines since the 1930s.
Thimerosal consists of 49.6% mercury by
weight and breaks down in the body to ethyl-
mercury and thiosalicylate (Tan and Parkin
2000). Recent reports have indicated that
some infants can receive ethylmercury (in the
form of thimerosal) at or above the U.S.
Environmental Protection Agency (EPA)
guidelines for methylmercury exposure (U.S.
EPA 2005), depending on the exact vaccina-
tions, schedule, and size of the infant (Ball
et al. 2001). Clements et al. (2000) calculated
that children receive 187.5 µg of ethylmercury
from thimerosal-containing vaccines given
over the first 14 weeks of life. According to
the authors, this amount approaches or, in
some cases, exceeds the U.S. EPA guidelines
for MeHg exposure during pregnancy
(0.1 µg/kg/day). Other estimates (Halsey
1999) have indicated that the schedule could
provide repeated doses of ethylmercury from
approximately 5 to 20 µg/kg over the first
6 months of life. Studies in preterm infants
indicate that blood levels of Hg after just one
vaccination (hepatitis B) increase by > 10-fold
to levels above the U.S. EPA guidelines
(Stajich et al. 2000).
The U.S. EPA guidelines for MeHg (U.S.
EPA 2005) are based on several decades of
studies of humans and animal models of
developmental toxicity (Burbacher et al.
1990a; National Research Council 2000).
Because few data exist for ethylmercury, the
use of the MeHg guidelines would seem
appropriate if the two compounds have similar
toxicokinetic proﬁles and neurodevelopmental
effects. The results from the few studies that
have provided a direct comparison of these
two compounds have been reviewed recently
by Magos (2003), who concluded that a)H g
clears from the body faster after the adminis-
tration of ethylmercury than after the admin-
istration of MeHg; b) the brain-to-blood Hg
concentration ratio established for MeHg will
overestimate Hg in the brain after exposure to
ethylmercury; and c) because ethylmercury
decomposes faster than MeHg, the risk of
brain damage is less for ethylmercury than for
MeHg. These conclusions are based on only a
few studies, none of which included measure-
ments of both blood and brain Hg levels in
infant subjects.
We initiated the present study in order to
directly compare the blood and brain levels of
Hg in infant nonhuman primates exposed
orally to MeHg or via intramuscular (im)
injections of vaccines containing thimerosal.
Nonhuman primates have been used exten-
sively in previous studies of MeHg toxico-
kinetics and developmental neurotoxicity
(Burbacher et al. 1986, 1990b; Gunderson
et al. 1986, 1988; Rice and Gilbert 1982,
1990, 1995; Stinson et al. 1989; Vahter et al.
1994, 1995). The routes of administration
(oral for MeHg and im injection for
thimerosal-containing vaccines) were chosen
to mimic the two routes of Hg exposure for
humans. The dosages and schedule of
administration of Hg were chosen to be com-
parable with the current immunization sched-
ule for human newborns, taking into
consideration the faster growth (~ 4 to 1) of
the macaque infant (Gunderson and Sackett
1984). The results of the present study pro-
vide important new information regarding
the comparative toxicokinetics of these two
compounds in newborns and infants.
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Thimerosal is a preservative that has been used in manufacturing vaccines since the 1930s.
Reports have indicated that infants can receive ethylmercury (in the form of thimerosal) at or
above the U.S. Environmental Protection Agency guidelines for methylmercury exposure, depend-
ing on the exact vaccinations, schedule, and size of the infant. In this study we compared the sys-
temic disposition and brain distribution of total and inorganic mercury in infant monkeys after
thimerosal exposure with those exposed to MeHg. Monkeys were exposed to MeHg (via oral gav-
age) or vaccines containing thimerosal (via intramuscular injection) at birth and 1, 2, and 3 weeks
of age. Total blood Hg levels were determined 2, 4, and 7 days after each exposure. Total and
inorganic brain Hg levels were assessed 2, 4, 7, or 28 days after the last exposure. The initial and
terminal half-life of Hg in blood after thimerosal exposure was 2.1 and 8.6 days, respectively,
which are significantly shorter than the elimination half-life of Hg after MeHg exposure at
21.5 days. Brain concentrations of total Hg were signiﬁcantly lower by approximately 3-fold for
the thimerosal-exposed monkeys when compared with the MeHg infants, whereas the average
brain-to-blood concentration ratio was slightly higher for the thimerosal-exposed monkeys (3.5 ±
0.5 vs. 2.5 ± 0.3). A higher percentage of the total Hg in the brain was in the form of inorganic
Hg for the thimerosal-exposed monkeys (34% vs. 7%). The results indicate that MeHg is not a
suitable reference for risk assessment from exposure to thimerosal-derived Hg. Knowledge of the
toxicokinetics and developmental toxicity of thimerosal is needed to afford a meaningful assess-
ment of the developmental effects of thimerosal-containing vaccines. Key words: brain and blood
distribution, elimination half-life, ethylmercury, infant nonhuman primates, methylmercury,
thimerosal. Environ Health Perspect 113:1015–1021 (2005). doi:10.1289/ehp.7712 available via
http://dx.doi.org/ [Online 21 April 2005]
ResearchMaterials and Methods
Subjects. Forty-one infant Macaca fascicularis
born at the Washington National Primate
Research Center’s Infant Primate Research
Laboratory were used in the study. The birth
weights of the infant monkeys were within the
normal range for this species; the average birth
weight was 341 g (range, 255–420 g). Infants
were weighed daily throughout the study, and
any clinical problems were recorded.
Mercury dosing schedule. The Hg dosing
schedule is shown in Table 1. Infants were
assigned to one of three exposure groups at
birth. Seventeen infant monkeys assigned to
the thimerosal group were given the typical
schedule of vaccines for human infants
(Table 1). Thimerosal (Omicron Quimica
S.A., Barcelona, Spain), dissolved in saline, was
mixed with thimerosal-free vaccines to yield a
ﬁnal concentration of 4, 8, or 20 µg/mL Hg,
depending on the vaccine and the age of the
infant. The total dose of Hg administered via
the vaccines was 20 µg/kg on day 0 and at 7,
14, and 21 days of age. A dose of 20 µg/kg was
chosen based on the range of estimated doses
received by human infants receiving vaccines
during the ﬁrst 6 months of life.
Seventeen infant monkeys assigned to the
MeHg group were given MeHg hydroxide
(MeHgOH, 97% pure; Alfa Aesar, Johnson
Matthey Co., Ward Hill, MA) dissolved in
water to a concentration of 20 µg Hg/mL.
MeHg was administered to infant monkeys
via oral gavage at a dose of 20 µg/kg on their
day of birth (day 0) and at 7, 14, and 21 days
of age.
Seven infant monkeys were assigned to a
control group. These monkeys did not receive
any gavages or im injections. Infants were
assigned to the three groups on a semirandom
basis, in order to balance sex ratios and aver-
age birth weights across groups.
Blood draw schedule. Blood was drawn
from the saphenous vein of all infant mon-
keys at birth (before any Hg exposure). Blood
was also drawn 2, 4, and 7 days after the ini-
tial Hg exposure (day 0) and after subsequent
exposures on days 7 and 14. Depending on
the sacrifice group, blood was drawn up to
28 days after the ﬁnal exposure on day 21 to
further characterize the washout kinetics of
Hg (Table 1).
Sacriﬁce schedule. Infants were sacriﬁced 2,
4, 7, or 28 days after their last Hg exposure on
day 21 (Table 1). Infants were sedated with an
im injection of ketamine (10 mg/kg) and
atropine (0.4 mg/kg) and then given an intra-
venous overdose of Nembutal (20 mg/kg;
Abbott Labs, North Chicago, IL). Autopsy
personnel from the primate center drew blood
and removed the brain and other organs
for analysis. The autopsy typically lasted
approximately 1 hr.
The numbers of monkeys at each sacriﬁce
day for both the MeHg and thimerosal groups
were as follows: day 23 (2 days after most
recent dose), n = 4; day 25 (4 days after most
recent dose), n = 4; day 28 (7 days after most
recent dose), n = 5; and day 49 (28 days after
most recent dose), n = 4. The seven control
monkeys were assigned sacrifice days as fol-
lows: day 23, n = 3; day 25, n = 1; day 28,
n = 2; and day 49, n = 1 (Table 1). Monkeys
were assigned to sacriﬁce groups at birth on a
semirandom basis that balanced sex ratios and
average birth weights across groups.
Blood and brain Hg measurements. Blood
samples were prepared for Hg analysis by
diluting them with an equal volume of 1%
wt/vol NaCl solution. Aliquots were removed
for Hg determination without digestion. One
drop of antifoam reagent was added to the
aliquot at the time of the analysis.
Half brain samples were fixed in for-
maldehyde before analysis. Samples of the ﬁx-
ative were analyzed to check for Hg content.
The tissue was removed from the jar and blot-
ted dry. A homogenate of the brain in 1%
NaCl was prepared using a Polytron homo-
genyzer PT 10-35 (Brinkmann Instruments,
Westbury, NY) while keeping the sample in
an ice slurry. An aliquot of the homogenate
was digested with 1 mL 1% wt/vol cysteine
and 2 mL 45% NaOH by heating at 95°C for
10–15 min. Digest was allowed to cool and
then diluted to volume by addition of 7 mL
1% wt/vol NaCl. The digests were kept in an
ice slurry until analysis. Aliquots were removed
for Hg determination. One drop of antifoam
was added to the aliquot at the time of
the analysis.
Total Hg concentrations in blood and total
and inorganic Hg concentrations in brain were
measured using a procedure adapted from
Greenwood et al. (1977). The method deter-
mines total Hg and its inorganic fraction
(Magos and Clarkson 1972). Cadmium chlo-
ride in the presence of stannous chloride at
high pH breaks the Hg–carbon bond with the
subsequent reduction of Hg2+ to Hg0; the lat-
ter is then measured by cold vapor atomic
absorption at 254 nm with a Hg monitor
(Laboratory Data Control, model 1235;
Thermo Separation Products, Waltham, MA).
Inorganic Hg is determined by the addition of
SnCl2 in the absence of cadmium chloride.
Concentration of organic Hg was calculated
from the difference between the measured
total and inorganic Hg concentrations. The
original concentration of SnCl2 used for the
Magos method (Magos and Clarkson 1972)
was modiﬁed to prevent the decomposition of
the ethylmercury during assay (Magos et al.
1985). To measure Hg in aqueous solution of
thimerosal, the amount of SnCl2 was reduced
from 100 µg to 50 µg/aliquot analyzed. For
tissue homogenate samples, 500 µg SnCl2 was
added to each aliquot. All reagents used for
preparation and analysis of the samples were
of analytical grade.
Quality control was assured by analysis
of reference samples before each assay run.
Fisher Mercury Reference Standard Solution
(SM114-100, certiﬁed 1,000 ppm ± 1%; Fisher
Scientiﬁc, Hampton, NH) was used as a stock
solution. Working standards of 30 and 10 ng
Hg/mL were made daily from appropriate dilu-
tions of the stock solution. In addition, the fol-
lowing certified reference materials were
analyzed daily before analysis of the samples:
trace elements in whole blood (Seronorm Trace
Elements, Certified Reference Material
201605, 6.8–8.5 µg/L; Accurate Chemical &
Scientiﬁc Corp., Westburg, NY), and trace ele-
ments in human hair (Certified Reference
Material 397, 12 µg/g ± 0.5; Commission of
the European Communities, Geel, Belgium).
The detection limit of the instrument was esti-
mated to be 0.75 ng Hg per aliquot used for
analysis.
Data analysis. The mean total blood Hg
concentration data from both the oral MeHg
and im thimerosal groups (n = 17 in each)
were analyzed using the compartmental mod-
ule of the pharmacokinetic modeling software
SAAM II (SAAM Institute, Seattle, WA).
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Table 1. Study design and schedule.
Age (days)
0 (birth) 2 4 7 9 11 14 16 18 21 23 25 28 31 35 38 42 45 49
MeHg group (oral dose, µg/kg) 20 20 20 20
OPV (0) OPV (0)
Thimerosal group [ethylmercury dose,  OPV (0) HB (4) OPV (0) HB (4)
in im vaccine (µg/kg)] HB (20) DTP (8) DTP (10) DTP (8)
Hib (8) Hib (10) Hib (8)
Blood draws (days after most recent dose) 0 2 4 7 2 4 7 2 4 7 2 4 7 10 14 17 21 24 28
Sacriﬁce day (days after last dose) 247 2 8
Abbreviations: DTP, diphtheria/tetanus/pertussis vaccine; HB, hepatitis B vaccine; HIB, haemophilus inﬂuenzae type b vaccine; OPV, oral polio vaccine. The accumulation and washout of total
blood Hg concentration–time data from the
MeHg monkeys were well described by a one-
compartment model featuring a first-order
absorption process. Regression ﬁt of the data to
the model yielded estimates of the absorption
rate constant (ka), elimination rate constant (K),
and an apparent volume of distribution (V/F; F
is the implicit bioavailability term). Half-lives
(T1/2) corresponding to each of the rate con-
stants were calculated by dividing ln 2 by the
rate constant estimate. Blood clearance (Cl/F)
was derived from the product of K and V/F.
A one-compartment model failed to
provide a satisfactory fit of the mean total
blood Hg concentration–time data from the
thimerosal monkeys. The model overpredicted
the blood concentration during accumula-
tion; at the same time, it underpredicted the
blood concentration during washout rate (i.e.,
overpredicted washout rate). Further exami-
nation of a scatter plot of the individual mon-
key data suggested a biphasic pattern in the
washout of Hg from the blood after the last
dose. Accordingly, we attempted a regression
ﬁt of the mean total blood Hg concentration
data with a two-compartment model. This
yielded a much better visual ﬁt of the data, with
minimal change in the objective function and
Akaike information criterion. The two-com-
partment parameter estimates from the regres-
sion analysis included the absorption rate
constant (ka), rate constants for Hg transfer
from the central to the peripheral compart-
ment (k12) and the return from the peripheral
to the central compartment (k21), the elimina-
tion rate constant from the central compart-
ment (k10), and the apparent volume of the
central compartment (Vc/F ). From these
primary parameters, we further estimated the
apparent distribution volume at steady state
(Vss/F) and the peripheral volume referenced
to blood concentration (i.e., Vp = Vss – Vc).
The initial and terminal rate constants and half-
lives (T1/2,α and T1/2,β) for the biexponential
decline of total blood Hg concentration were
estimated by standard formulas (Gibaldi and
Perrier 1982). Blood clearance was computed
by the product of Vc and k10. For both the
MeHg and thimerosal model ﬁts, a fractional
SD of 0.1 was used as the weighting scheme.
The washout half-life of total and organic
Hg in the brain of both the oral MeHg and
im thimerosal groups was estimated by
regression fit to a monoexponential model
using WinNonlin software (Pharsight Corp.,
Mountain View, CA). One of the day 28
brain samples from the MeHg exposure group
had a spuriously high total Hg concentration,
that is, a concentration of 151 ng/g, which is
more than 50% higher than the other samples
obtained on day 28 (71–90 ng/mL) and higher
than those observed at the earliest sacriﬁce time
at day 2 (75–129 ng/g). The unreasonably
high concentration is most likely due to conta-
mination of the sample. Therefore, data from
this brain and its corresponding blood were
excluded from the regression analysis. The aver-
age brain-to-blood concentration ratio was also
calculated using data from the earliest sacriﬁce
duration (2 days). Because of different washout
half-lives in blood and the brain, brain-to-blood
concentration ratio is expected to vary with the
duration of washout. Samples at day 2 offered
the best measure of the extent of uptake of Hg
species into the brain that are least confounded
by differences in their clearance rate.
Between-group statistical comparisons of
the rate of washout of total Hg in blood, as well
as total and organic concentrations in the brain,
were accomplished through multiple regression
analysis as implemented in the PROC GLM
subroutine in SAS (version 9.1; SAS Institute,
Cary, NC). PROC GLM performs multiple
regression within the framework of general lin-
ear models and can accommodate missing data
or sparse sampling and confounding from corre-
lations between repeated measures. Hence, it is
able to provide tests of hypotheses for the effects
of time and group using blood and brain data
obtained from sacriﬁce of individual animals at
varying times during washout. Log-transformed
blood or brain Hg concentrations in animals
from both the MeHg and thimerosal groups
were entered as the dependent variable. The
independent variables consisted of sampling
time, group (MeHg = 0, thimerosal = 1), and a
time-by-group interaction. Once the overall sig-
niﬁcance of the regression model was veriﬁed,
the signiﬁcant sources of variation (i.e., time,
group, and time by group) were identiﬁed. A
difference in the rate of washout of Hg in blood
or brain between groups was indicated by a sig-
niﬁcant regression coefﬁcient for time-by-group
interaction. If there was no evidence for inter-
action, a signiﬁcant decline in blood or brain
Hg concentration over time for each group was
assessed by the t-statistic associated with the
estimated regression coefﬁcient for time.
The following statistical comparisons of
the washout rate of Hg were also undertaken:
total Hg in blood versus total Hg in the brain,
total Hg in blood versus organic Hg in the
brain, and total Hg versus organic Hg concen-
tration in the brain. The difference between
the pair of log-transformed Hg concentrations
for each animal sacriﬁced at the various times
was calculated. Individual difference values in
both groups were then entered as the depen-
dent variable in the regression model. The
independent variables were time, group, and
time-by-group interaction. A significant
regression coefficient for the time variable
indicates that the paired-log concentration dif-
ference (or the concentration ratio) varied
with time; that is, the two concentration
measures (e.g., blood and brain) did not
decline in parallel with time.
Results
Growth and health status. The weights of
infant monkeys during the study are shown in
Figure 1. We found no signiﬁcant differences
in the weight gain across the three groups
(p > 0.10, all comparisons); the average weight
gain during the ﬁrst 23 days of life was 135 g.
The brain weights at sacrifice and brain-to-
body weight ratios are shown in Table 2; we
found no significant differences in brain
weights or brain-to-body weight ratios across
Thimerosal and blood and brain mercury
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Figure 1. Weight gain of infant monkeys during study. Error bars indicate SE.
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Table 2. Mean ± SE body and brain weight and brain-to-body weight ratio at sacriﬁce.
Exposure group Body weight (g) Brain weight (g) Brain:body weight ratio
Controls (n = 9) 509.3 ± 52.0 52.1 ± 2.5 0.107 ± 0.009
MeHg exposed (n = 17) 499.1 ± 17.5 51.1 ± 1.1 0.103 ± 0.003
Thimerosal exposed (n = 17) 529.1 ± 25.4 52.7 ± 1.2 0.102 ± 0.003the three groups (p > 0.10, all comparisons).
Also, no serious medical complications were
observed in any of the monkeys.
Oral MeHg kinetics. The total blood Hg
concentrations at 2 days (observed peak) after
the first dose ranged from 8 to 18 ng/mL
across the monkeys, that is, a 2-fold variation.
Progressive accumulation of total blood Hg
was observed over the three subsequent doses
of MeHg, such that the peak total blood Hg
concentrations after the fourth dose were
about 3-fold higher (30–46 ng/mL). The
interanimal variation in blood Hg concentra-
tions remained at about 2-fold during accu-
mulation. Blood Hg persisted through the
entire period of washout and was readily
measurable in all four monkeys in the 28 day
sacriﬁce group (16–21 ng/mL). This is consis-
tent with previous reports of an elimination
T1/2 > 20 days for MeHg in adult M. fascicu-
laris (Stinson et al. 1989; Vahter et al. 1994,
1995) and explains the minimal decline
(< 20%) in blood Hg concentrations during
the weekly intervals between MeHg doses.
The time course of total blood Hg was ﬁt-
ted to a one-compartment model. Figure 2
shows the excellent regression ﬁt of the mean
blood concentration–time data. Table 3 pre-
sents parameter estimates from the one-com-
partment model fit of the mean blood Hg
concentration–time data. The distribution
volume of total Hg after MeHg administra-
tion is estimated to be 1.7 L/kg, or about
20 times the blood volume (~ 8%). This
means that only 1/20th of the body burden of
Hg is conﬁned to the vascular space. This is
consistent with the known extensive extravas-
cular distribution of Hg after MeHg exposure
in primates and agrees with previous estimates
of Hg distribution volume in adult M. fascic-
ularis (Stinson et al. 1989). The elimination
T1/2 of total blood Hg is 21.5 days, which
agrees with reported estimates in adult M. fas-
cicularis (Stinson et al. 1989; Vahter et al.
1994, 1995). The blood clearance is esti-
mated at 46.1 mL/day/kg, well within the
range of clearance values observed earlier in
adult M. fascicularis (Stinson et al. 1989). It
appears that the systemic disposition kinetics
of MeHg are the same between infant and
adult M. fascicularis, that is, no change during
development.
A plot of the blood and brain total Hg
concentration data from the monkeys sacri-
ficed at various times during the washout
period is shown in Figure 3. There was a sig-
nificant decrease in total Hg from the blood
during the washout period (p < 0.01). The
apparent T1/2 for total Hg in blood is 19.1 ±
5.1 days (± SE of regression estimate). The
decrease in total Hg in the brain over time was
marginally significant (p < 0.07), with an
apparent T1/2 of 59.5 ± 24.1 days. The T1/2 for
total Hg in brain was signiﬁcantly longer than
the T1/2 for total Hg in blood (p = 0.05) for
the MeHg-exposed monkeys. The T1/2 for
total Hg in brain is also longer than the previ-
ously reported washout T1/2 from the brain for
adult M. fascicularis (37 days; Vahter et al.
1994, 1995). It should be noted that the rela-
tively high SE of the half-life estimates for the
brain reﬂects the large interanimal variation in
Hg concentrations at each sampling time, lim-
ited number of data points, and the short dura-
tion of sacriﬁce relative to the washout half-life.
The concentration of total Hg in the brain is
1.7- to 3-fold higher than in the blood (mean
± SE of 2.5 ± 0.3) 2 days after the last MeHg
dose. This brain-to-blood concentration ratio
increased as the duration between the last dose
and the sacriﬁce lengthened. The ratio ranged
from 3.9 to 7.4 at 28 days after the last expo-
sure. The time dependence for the brain-to-
blood ratio (p = 0.06) is primarily due to the
difference in the washout T1/2 between total
Hg in the blood and brain. The average brain-
to-blood ratio for these infant monkeys at
day 2 after the last MeHg dose (2.5 ± 0.3) is
slightly lower than previously reported values
(3–5) for adult macaque and squirrel monkeys
over various durations of washout (Berlin et al.
1975; Stinson et al. 1989; Vahter et al. 1994).
Although the cited differences in brain uptake
and clearance of MeHg between adult and
infant monkeys may be attributed to the effects
of postnatal brain growth and development, it
may also be related to variation in exposure
regimen between studies.
A plot of the organic and inorganic Hg
concentrations in the brain of MeHg-exposed
monkeys sacriﬁced at various times during the
washout period is shown in Figure 4. The
decrease in organic Hg in the brain over time
was not statistically signiﬁcant (p = 0.17). The
apparent T1/2 for the washout of organic Hg
from the brain was 58.4 ± 25.0 days, close to
the T1/2 for total Hg. The concentration of
inorganic Hg in the brain samples was below
the quantiﬁable limit of the assay (7 ng/mL) in
8 of 17 MeHg-exposed monkeys. The average
concentration of inorganic Hg for those
monkeys with values above the detection
limit (n = 10) did not change significantly
over 28 days of washout and was approxi-
mately 7–8 ng/mL (Figure 4). Inorganic Hg
represented only 6–10% of total Hg in the
Burbacher et al.
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Figure 2. Comparison of predicted and observed
mean blood total Hg concentrations during and
after four weekly oral doses (20 µg/kg) of MeHg.
Error bars indicate SD. 
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Table 3. Parameter estimates derived from a one-
compartment analysis of the mean blood total Hg
concentration for the oral MeHg group (n = 17).
Model parameters Mean ± SD
V/F (L/kg) 1.67 ± 0.07
ka (day–1) 2.07 ± 1.04
K (day–1) 0.0276 ± 0.0024
T1/2 (days) 21.5
Cl/F (mL/day/kg) 46.1
Figure 3. A semilogarithmic plot of washout of total
Hg in blood and the brain after four weekly oral
doses (20 µg/kg) of MeHg. The data were collected
from groups of infant monkeys sacriﬁced 2, 4, 7, and
28 days after the last dose. The lines represent non-
linear regression ﬁt of the data to a monoexponen-
tial model; the regression estimate (± SE) of T1/2 is
T1/2 = 19.1 ± 5.1 days (r = 0.81) for blood and T1/2 =
59.5 ± 24.1 days (r = 0.59) for brain.
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Figure 4. A semilogarithmic plot of the washout of
organic and inorganic Hg in the brain after four
weekly oral doses (20 µg/kg) of MeHg. The data
were collected from groups of infant monkeys sac-
riﬁced at 2, 4, 7, and 28 days after the last dose. The
lines represent nonlinear regression ﬁt of the data
to a monoexponential model. The regression esti-
mate (± SE) for organic Hg is T1/2 = 58.4 ± 25.0 days
(r = 0.57). The half-life of inorganic Hg is too long
(> 120 days) to be accurately estimated from the pre-
sent data (i.e., ris not signiﬁcantly different from 0). 
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ously reported data in adult M. fascicularis
(Vahter et al. 1994, 1995).
Intramuscular thimerosal kinetics. The ini-
tial total Hg concentrations in the day 2 blood
samples, which ranged from 6 to 14 ng/mL, are
comparable with the concentrations observed in
the oral MeHg group. These blood levels are
also similar to those reported in preterm human
infants receiving 12.5 µg Hg from a hepatitis B
vaccine (Stajich et al. 2000). Blood Hg concen-
trations declined relatively rapidly (by > 50%)
between doses. As a result, there was minimal
accumulation in blood Hg concentrations dur-
ing weekly dosing. Also, blood Hg concentra-
tions dropped below the detection limit of the
assay in some animals by day 10 after the last
vaccine injection.
The time course of total blood Hg
concentrations was best described by a two-
compartment model; that is, the disposition
kinetics are biphasic, with a rapid initial phase
followed by a slower terminal phase of clear-
ance. Table 4 presents the parameter estimates
derived from the two-compartment model
analysis. A comparison of the model prediction
and the observed blood concentration data is
shown in Figure 5. The model predicted some
accumulation in peak blood Hg concentrations
and minimal accumulation in trough concen-
trations. Because blood concentration data
were not available before day 2, the predicted
peak concentrations are extrapolations and
should be viewed with caution. The initial vol-
ume of distribution in the central compart-
ment was 1.7 L/kg, which is comparable with
the overall distribution volume for oral MeHg.
The initial and terminal blood half-lives were
2.1 and 8.6 days, respectively. Mercury derived
from thimerosal is eliminated much more
rapidly than MeHg. The steady-state volume
of distribution (i.e., Vss or the fully equilibrated
volume) was estimated to be 2.5 L/kg, which is
50% larger than the initial distribution volume
(i.e., Vc). Hence, the effective peripheral com-
partment volume at steady state is about
0.8 L/kg. Alternately, this means that, at steady
state, partitioning of the body burden of Hg
between the tissue regions associated with the
central and peripheral compartments is about
2:1. The blood clearance of total Hg was esti-
mated to be 248 mL/day/kg, which is 5.4-fold
higher than the estimate for oral MeHg.
Figure 6 presents a scatter plot of the blood
and brain total Hg concentration data for mon-
keys sacrificed at various times during the
washout. There was a significant decrease in
total Hg concentration in the blood during the
washout period (p < 0.01). The apparent T1/2
for total Hg in blood is 6.9 ± 1.7 days. There
was also a signiﬁcant decrease in total Hg con-
centration in the brain over time (p < 0.01),
with an apparent T1/2 of 24.2 ± 7.4 days. The
T1/2 for total Hg in brain was significantly
longer than the T1/2 for total Hg in blood
(p < 0.01) for the thimerosal-exposed monkeys.
In addition, the T1/2 for total Hg in blood and
brain for these monkeys (6.9 ± 1.7 days and
24.2 ± 7.4 days, respectively) are signiﬁcantly
shorter (p < 0.01) than the T1/2 for total Hg in
blood and brain for the MeHg monkeys (19.1
± 5.1 days and 59.5 ± 24.1 days). The concen-
tration of total Hg in the brain of the
thimerosal-exposed monkeys is 2.6- to 4.6-fold
higher than in the blood (mean ± SE, 3.5 ± 0.5)
at 2 days after the last injection. Again, this
ratio increased as the sacriﬁce was performed at
longer durations from the last dose, primarily
due to the difference in the half-lives of total
Hg in the blood and brain.
A plot of the organic and inorganic Hg
concentrations in the brain of thimerosal-
exposed infant monkeys sacrificed at various
times during the washout period is shown in
Figure 7. There was a significant decrease in
organic Hg in the brain over the washout
period (p < 0.01). The apparent T1/2 for the
washout of organic Hg from the brain was
14.2 ± 5.2 days, which is signiﬁcantly shorter
than the T1/2 for total Hg in brain (p < 0.01).
The inorganic form of Hg was readily measur-
able in the brain of the thimerosal-exposed
monkeys. The average concentration of inor-
ganic Hg did not change across the 28 days of
washout and was approximately 16 ng/mL
(Figure 7). This level of inorganic Hg repre-
sented 21–86% of the total Hg in the brain
(mean ± SE, 70 ± 4%), depending on the sacri-
ﬁce time. These values are considerably higher
than the inorganic fraction observed in the
brain of MeHg monkeys (6–10%).
Discussion
There are notable similarities and differences
in the kinetics of Hg after oral administration
of MeHg and im injection of thimerosal in
vaccines. The absorption rate and initial distri-
bution volume of total Hg appear to be simi-
lar between im thimerosal and oral MeHg.
This means approximately equal peak total
blood Hg levels after a single exposure to
Thimerosal and blood and brain mercury
Environmental Health Perspectives • VOLUME 113 | NUMBER 8 | August 2005 1019
Figure 5. Comparison of predicted and observed
mean blood total Hg concentration during and after
four weekly im injections of vaccine containing
thimerosal (20 µg/kg Hg). Error bars indicate SD. 
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Figure 6. A semilogarithmic plot of washout of total
Hg in blood and the brain after four weekly im injec-
tions of vaccine thimerosal (20 µg/kg Hg). The data
were collected from groups of infant monkeys sacri-
ﬁced at 2, 4, 7, 10, 17, and 21 days after the last dose.
The lines represent nonlinear regression fit of the
data to a monoexponential model. The regression
estimate (± SE) of T1/2 is 24.2 ± 7.4 days (r = 0.74) for
brain and 6.9 ± 1.7 days (r = 0.82) for blood. 
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Table 4. Parameter estimates derived from a two-
compartment analysis of the mean blood total Hg
concentration for the im thimerosal group (n = 17).
Model parameters Mean ± SD
ka (day–1) 3.24 ± 3.00
k12 (day–1) 0.081 ± 0.076
k21 (day–1) 0.177 ± 0.138
k10 (day–1) 0.148 ± 0.024
T1/2, α (day) 2.13
T1/2,β (day) 8.62
Vc/F (L/kg) 1.68 ± 0.30
Vss/F (L/kg) 2.45
Vp (L/kg) 0.77
Cl/F (mL/day/kg) 248
Figure 7. A semilogarithmic plot of washout of
organic and inorganic Hg in the brain after four
weekly im injection of vaccines containing
thimerosal (20 µg/kg Hg). The data were collected
from groups of infant monkeys sacriﬁced at 2, 4, 7,
and 28 days after the last dose. The lines represent
nonlinear regression ﬁt of the data to a monoexpo-
nential model. The regression estimate (± SE) of
T1/2 for organic Hg is T1/2 = 14.2 ± 5.2 days (r = 0.76).
The half-life of inorganic Hg is too long (> 120 days)
to be accurately estimated from the present data
(i.e., r is not signiﬁcantly different from 0). 
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Inorganiceither MeHg or thimerosal or after episodic
exposures that are apart by longer than four
elimination half-lives (i.e., > 80 days for
MeHg or > 28 days for thimerosal). Studies in
preterm and term human infants have
reported similar results (Stajich et al. 2000).
Infants receiving 12.5 µg Hg from a single
hepatitis B vaccine had blood Hg levels at
48–72 hr, consistent with what would be
anticipated after an equivalent dose of MeHg.
Although the initial distribution volume of
total Hg is similar for the two groups, a bipha-
sic exponential decline in total blood Hg is
observed only after im injections of thimerosal.
This suggests continual distribution into and
localization in tissue sites over time. It is rele-
vant to note that the kidney-to-blood concen-
tration gradient of total Hg is much higher in
the thimerosal monkeys than in the MeHg
monkeys (mean ± SE, 95.1 ± 10 vs. 5.8 ± 0.6).
The second slower phase of washout could also
represent the gradual biotransformation of
ethylmercury (the presumed principal organic
form of Hg after thimerosal administration) to
Hg-containing metabolites that have a differ-
ent tissue distribution or are more slowly elimi-
nated. Further investigations of the disposition
fate of thimerosal-derived Hg should address
these issues.
Total Hg derived from im thimerosal is
cleared from the infant M. fascicularis much
more quickly than MeHg. The washout T1/2
of total blood Hg after im injections of
thimerosal in vaccines is much shorter than the
T1/2 of MeHg (6.9 vs. 19.1 days). These results
support the earlier conclusion of Magos (2003)
that Hg is cleared from the body faster after
the administration of ethylmercury than after
the administration of MeHg. More interest-
ingly, the washout blood Hg T1/2 in the
thimerosal-exposed infant macaques (7 days) is
remarkably similar to the blood Hg T1/2
reported for human infants injected with
thimerosal-containing vaccines reported by
Pichichero et al. (2002).
An important consequence of the difference
in blood half-lives is the remarkable accumula-
tion of blood Hg during repeated exposure to
MeHg. Although the initial blood Hg concen-
tration (at 2 days after the ﬁrst dose) did not
differ between the MeHg and thimerosal
groups, the peak blood Hg concentration in the
MeHg-exposed monkeys rose to a level nearly
three times higher than in the thimerosal mon-
keys after the fourth dose. Furthermore, the
blood clearance of total Hg is 5.4-fold higher
after im thimerosal than after oral MeHg expo-
sure. The results indicate that for an equivalent
level of chronic exposure, the area under the
curve of total blood Hg concentrations in
human infants receiving repeated im injections
of thimerosal-containing vaccines will be 
signiﬁcantly lower than that in those exposed
chronically to MeHg via the oral route.
A much lower brain concentration of total
Hg was observed in the thimerosal monkeys
compared with the MeHg monkeys, that is, a
3- to 4-fold difference for an equivalent expo-
sure of Hg. Moreover, total Hg is cleared
much more rapidly from the brain after
thimerosal than after MeHg exposure (24 vs.
60 days). It appears that the difference in brain
Hg exposure between thimerosal and MeHg is
largely driven by their differences in systemic
disposition kinetics (i.e., the blood level). The
average brain-to-blood partitioning ratio of
total Hg in the thimerosal group was slightly
higher than that in the MeHg group (3.5 ± 0.5
vs. 2.5 ± 0.3, t-test, p = 0.11). Thus, the brain-
to-blood Hg concentration ratio established for
MeHg will underestimate the amount of Hg in
the brain after exposure to thimerosal.
The large difference in the blood Hg half-
life compared with the brain half-life for the
thimerosal-exposed monkeys (6.9 days vs.
24 days) indicates that blood Hg may not be a
good indicator of risk of adverse effects on the
brain, particularly under conditions of rapidly
changing blood levels such as those observed
after vaccinations. The blood concentrations of
the thimerosal-exposed monkeys in the present
study are within the range of those reported for
human infants after vaccination (Stajich et al.
2000). Data from the present study support
the prediction that, although little accumula-
tion of Hg in the blood occurs over time with
repeated vaccinations, accumulation of Hg in
the brain of infants will occur. Thus, conclu-
sion regarding the safety of thimerosal drawn
from blood Hg clearance data in human
infants receiving vaccines may not be valid,
given the signiﬁcantly slower half-life of Hg in
the brain as observed in the infant macaques.
There was a much higher proportion of
inorganic Hg in the brain of thimerosal mon-
keys than in the brains of MeHg monkeys (up
to 71% vs. 10%). Absolute inorganic Hg con-
centrations in the brains of the thimerosal-
exposed monkeys were approximately twice
that of the MeHg monkeys. Interestingly, the
inorganic fraction in the kidneys of the same
cohort of monkeys was also signiﬁcantly higher
after im thimerosal than after oral MeHg expo-
sure (0.71 ± 0.04 vs. 0.40 ± 0.03). This sug-
gests that the dealkylation of ethylmercury is
much more extensive than that of MeHg.
Previous reports have indicated that the
dealkylation of Hg is a detoxiﬁcation process
that helps to protect the central nervous sys-
tem (Magos 2003; Magos et al. 1985). These
reports are largely based on histology and his-
tochemistry studies of adult rodents exposed
to Hg for a short period of time. The results of
these studies indicated that damage to the
cerebellum was observed only in MeHg-
treated animals that had much lower levels of
inorganic Hg in the brain than animals com-
parably treated with ethylmercury. Moreover,
the results did not indicate the presence of
inorganic Hg deposits in the area where the
cerebellar damage was localized (granular layer).
In contrast, previous studies of adult
M. fascicularis monkeys exposed chronically
to MeHg have indicated that demethylation
of Hg occurs in the brain over a long period
of time after MeHg exposure and that this is
not a detoxiﬁcation process (Charleston et al.
1994, 1995, 1996; Vahter et al. 1994, 1995).
Results from these studies indicated higher
inorganic Hg concentrations in the brain
6 months after MeHg exposure had ended,
whereas organic Hg had cleared from the
brain. The estimated half-life of organic Hg
in the brain of these adult monkeys was con-
sistent across various brain regions at approxi-
mately 37 days (similar to the brain half-life
in the present infant monkeys). The esti-
mated half-life of inorganic Hg in the brain in
the same adult cohort varied greatly across
some regions of the brain, from 227 days to
540 days. In other regions, the concentrations
of inorganic Hg remained the same (thala-
mus) or doubled (pituitary) 6 months after
exposure to MeHg had ended (Vahter et al.
1994, 1995). Stereologic and autometallo-
graphic studies on the brains of these adult
monkeys indicated that the persistence of
inorganic Hg in the brain was associated with
a significant increase in the number of
microglia in the brain, whereas the number of
astrocytes declined. Notably, these effects
were observed 6 months after exposure to
MeHg ended, when inorganic Hg concentra-
tions were at their highest levels, or in animals
solely exposed to inorganic Hg (Charleston
et al. 1994, 1995, 1996). The effects in the
adult macaques were associated with brain
inorganic Hg levels approximately ﬁve times
higher than those observed in the present
group of infant macaques. The longer-term
effects (> 6 months) of inorganic Hg in the
brain have not been examined. In addition,
whether similar effects are observed at lower
levels in the developing brain is not known. It
is important to note that “an active neuroin-
ﬂammatory process” has been demonstrated in
brains of autistic patients, including a marked
activation of microglia (Vargas et al. 2005).
The American Academy of Pediatrics
and the U.S. Public Health Service (1999) pub-
lished a joint statement that urged “all govern-
ment agencies to work rapidly toward reducing
children’s exposure to mercury from all
sources.” The statement recommended that
thimerosal be removed from vaccines as soon as
possible as part of this overall process. Between
1999 and 2001, vaccines currently recom-
mended for children ≤ 6 years of age were made
available in thimerosal-free formulations in the
United States (Centers for Disease Control and
Prevention 2001). Exposures to thimerosal
through pediatric vaccines, however, still occur
Burbacher et al.
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in other countries where multiple-dose vials are
used to maintain childhood immunization pro-
grams and the control of preventable disease
(Knezevic et al. 2004). 
Recent publications have proposed a direct
link between the use of thimerosal-containing
vaccines and the signiﬁcant rise in the number
of children being diagnosed with autism, a
serious and prevalent developmental disorder
(for review, see IOM 2001). Results from an
initial IOM review of the safety of vaccines
found that there was not sufﬁcient evidence to
render an opinion on the relationship between
ethylmercury exposure and developmental dis-
orders in children (IOM 2001). The IOM
review did, however, note the possibility of
such a relationship and recommended further
studies be conducted. A recently published
second review (IOM 2004) appears to have
abandoned the earlier recommendation as well
as backed away from the American Academy
of Pediatrics goal. This approach is difﬁcult to
understand, given our current limited knowl-
edge of the toxicokinetics and developmental
neurotoxicity of thimerosal, a compound that
has been (and will continue to be) injected in
millions of newborns and infants.
The key ﬁndings of the present study are
the differences in the disposition kinetics and
demethylation rates of thimerosal and MeHg.
Consequently, MeHg is not a suitable refer-
ence for risk assessment from exposure to
thimerosal-derived Hg. Knowledge of the bio-
transformation of thimerosal, the chemical
identity of the Hg-containing species in the
blood and brain, and the neurotoxic potential
of intact thimerosal and its various biotransfor-
mation products, including ethylmercury, is
urgently needed to afford a meaningful inter-
pretation of the potential developmental effects
of immunization with thimerosal-containing
vaccines in newborns and infants. This infor-
mation is critical if we are to respond to public
concerns regarding the safety of childhood
immunizations.
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In the original manuscript published online,
there were two errors that have been corrected
here. First, in the Abstract, the standard errors
for the average brain-to-blood concentration
ratios were incorrect for thimerosal and
MeHg-exposed monkeys. Second, in the last
paragraph of “Data analysis,” the statement
about the two concentration measures has
been corrected to “the two concentration
measures (e.g., blood and brain) did not
decline in parallel with time.”